GSK vs. IDXX: A Head-to-Head Stock Comparison

Updated on November 22, 2025

Here’s a clear look at GSK and IDXX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

GSK trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, IDXX is a standard domestic listing.

Symbol	GSK	IDXX
Company Name	GSK plc	IDEXX Laboratories, Inc.
Country	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Health Care Equipment & Supplies
Market Capitalization	95.87 billion USD	54.36 billion USD
Exchange	NYSE	NasdaqGS
Listing Date	March 28, 1980	June 21, 1991
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of GSK and IDXX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

GSK vs. IDXX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	GSK	IDXX
5-Day Price Return	0.68%	-2.77%
13-Week Price Return	25.19%	6.01%
26-Week Price Return	30.94%	35.51%
52-Week Price Return	36.18%	60.52%
Month-to-Date Return	0.20%	9.60%
Year-to-Date Return	32.49%	66.88%
10-Day Avg. Volume	5.00M	0.65M
3-Month Avg. Volume	5.60M	0.54M
3-Month Volatility	24.95%	35.41%
Beta	0.97	1.66

Profitability

Return on Equity (TTM)

GSK

37.40%

Pharmaceuticals Industry

Max: 38.95%
Q3: 20.34%
Median: 11.59%
Q1: 3.32%
Min: -10.91%

In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 37.40% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

IDXX

67.78%

Health Care Equipment & Supplies Industry

Max: 29.82%
Q3: 15.54%
Median: 9.69%
Q1: 5.19%
Min: -7.98%

IDXX’s Return on Equity of 67.78% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

GSK vs. IDXX: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

GSK

17.08%

Pharmaceuticals Industry

Max: 39.07%
Q3: 19.28%
Median: 13.48%
Q1: 5.73%
Min: -8.86%

GSK’s Net Profit Margin of 17.08% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

IDXX

24.65%

Health Care Equipment & Supplies Industry

Max: 24.65%
Q3: 14.10%
Median: 10.09%
Q1: 5.84%
Min: -6.13%

A Net Profit Margin of 24.65% places IDXX in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.

GSK vs. IDXX: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

GSK

23.42%

Pharmaceuticals Industry

Max: 45.58%
Q3: 24.35%
Median: 18.05%
Q1: 7.58%
Min: -11.88%

GSK’s Operating Profit Margin of 23.42% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

IDXX

31.34%

Health Care Equipment & Supplies Industry

Max: 31.34%
Q3: 18.36%
Median: 15.07%
Q1: 9.62%
Min: -0.13%

An Operating Profit Margin of 31.34% places IDXX in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

GSK vs. IDXX: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	GSK	IDXX
Return on Equity (TTM)	37.40%	67.78%
Return on Assets (TTM)	9.13%	31.08%
Net Profit Margin (TTM)	17.08%	24.65%
Operating Profit Margin (TTM)	23.42%	31.34%
Gross Profit Margin (TTM)	72.52%	61.72%

Financial Strength

Current Ratio (MRQ)

GSK

0.84

Pharmaceuticals Industry

Max: 5.45
Q3: 2.99
Median: 1.98
Q1: 1.29
Min: 0.78

GSK’s Current Ratio of 0.84 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

IDXX

1.18

Health Care Equipment & Supplies Industry

Max: 4.97
Q3: 2.92
Median: 2.12
Q1: 1.54
Min: 0.86

IDXX’s Current Ratio of 1.18 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

GSK vs. IDXX: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

GSK

1.10

Pharmaceuticals Industry

Max: 1.79
Q3: 0.78
Median: 0.31
Q1: 0.08
Min: 0.00

GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.10. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

IDXX

0.63

Health Care Equipment & Supplies Industry

Max: 1.62
Q3: 0.74
Median: 0.47
Q1: 0.15
Min: 0.00

IDXX’s Debt-to-Equity Ratio of 0.63 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

GSK vs. IDXX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

GSK

2.37

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 10.15
Q1: 2.37
Min: -42.71

GSK’s Interest Coverage Ratio of 2.37 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

IDXX

49.24

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 24.86
Median: 9.84
Q1: 3.86
Min: -21.65

IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

GSK vs. IDXX: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	GSK	IDXX
Current Ratio (MRQ)	0.84	1.18
Quick Ratio (MRQ)	0.55	0.82
Debt-to-Equity Ratio (MRQ)	1.10	0.63
Interest Coverage Ratio (TTM)	2.37	49.24

Growth

Revenue Growth

GSK vs. IDXX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

GSK vs. IDXX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

GSK

3.53%

Pharmaceuticals Industry

Max: 6.72%
Q3: 3.48%
Median: 1.90%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 3.53%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 4.36%
Q3: 1.87%
Median: 0.82%
Q1: 0.00%
Min: 0.00%

IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

GSK vs. IDXX: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

GSK

46.05%

Pharmaceuticals Industry

Max: 199.58%
Q3: 85.87%
Median: 49.36%
Q1: 1.12%
Min: 0.00%

GSK’s Dividend Payout Ratio of 46.05% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 67.77%
Median: 28.21%
Q1: 0.00%
Min: 0.00%

IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

GSK vs. IDXX: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	GSK	IDXX
Dividend Yield (TTM)	3.53%	0.00%
Dividend Payout Ratio (TTM)	46.05%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

GSK

13.05

Pharmaceuticals Industry

Max: 52.64
Q3: 29.89
Median: 20.77
Q1: 13.37
Min: 5.71

In the lower quartile for the Pharmaceuticals industry, GSK’s P/E Ratio of 13.05 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

IDXX

52.75

Health Care Equipment & Supplies Industry

Max: 67.59
Q3: 41.41
Median: 33.11
Q1: 22.82
Min: 8.68

A P/E Ratio of 52.75 places IDXX in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

GSK vs. IDXX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

GSK

2.23

Pharmaceuticals Industry

Max: 8.74
Q3: 4.66
Median: 2.37
Q1: 1.67
Min: 0.11

GSK’s P/S Ratio of 2.23 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

IDXX

13.00

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.92
Q1: 1.97
Min: 0.61

With a P/S Ratio of 13.00, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

GSK vs. IDXX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

GSK

3.97

Pharmaceuticals Industry

Max: 9.86
Q3: 5.28
Median: 2.48
Q1: 1.57
Min: 0.59

GSK’s P/B Ratio of 3.97 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

IDXX

32.74

Health Care Equipment & Supplies Industry

Max: 10.77
Q3: 6.04
Median: 3.32
Q1: 2.31
Min: 0.83

At 32.74, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

GSK vs. IDXX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	GSK	IDXX
Price-to-Earnings Ratio (TTM)	13.05	52.75
Price-to-Sales Ratio (TTM)	2.23	13.00
Price-to-Book Ratio (MRQ)	3.97	32.74
Price-to-Free Cash Flow Ratio (TTM)	15.26	57.64